Media Centre
Press Releases
Press Releases
This site uses session cookies only. These enable core functionality and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
ContinueWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy
Engitix appoints two additional international biotech industry leaders as Scientific Advisors
London, UK – 25 June 2024 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of two biotech industry leaders as Scientific Advisors: Adrian S. Ray, PhD, and Scott Turner, PhD. These appointments support […]
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences
London, UK – 21st May 2024 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of Matthew Edwards, Ph.D., as Senior Vice President of Discovery Sciences, and Emma Huang, Ph.D., as Vice President […]
Engitix Announces Appointment of Christopher Stevenson Ph.D., as Chief Scientific Officer
London, UK – 5 September 2023 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary patient-centric human extracellular matrix (ECM) platform, today announces the appointment of Christopher (Chris) Stevenson, Ph.D. as Chief Scientific Officer (CSO). In this new role, Chris will be responsible […]
Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
London, UK – 9 May 2023 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of Sonia Quaratino, M.D., PH.D., to its Board of Directors, as an independent non-executive director. Dr. Quaratino has over […]
Engitix Celebrates Move to Expanded Purpose-designed Facilities in White City, West London
London, UK – 5 October 2022 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today celebrated its expansion and growth with a Grand Opening at its new facilities in White City, West London. Engitix purpose-designed mixed-use headquarters and R&D […]
Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease
Collaboration combines Engitix’s unique human extracellular matrix (ECM) platform with Takeda’s expertise in gastroenterology research and development (R&D) and commercialisation.
Engitix Announces $54m Series A Financing and a Strategic Collaboration with Dompé Farmaceutici Using Exscalate’s AI Supercomputing Power to Advance its Drug Discovery Pipeline in Fibrosis and Cancer
$54m series A financing co-led by existing investor Netherton Investments (a fund investing on behalf of Mike Platt) and new investor Dompé farmaceutici S.P.A (an Italian and US-based biopharmaceutical company)
Engitix Therapeutics appoints Dr Mike Burbridge as VP Oncology and Immuno-oncology
London, UK – 4 May 2021 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology. Dr […]
Engitix Therapeutics strengthens management team with new directors for fibrosis and computational biology
Company is on expansion curve with two new appointments and recent move to larger facilities London, UK – 23 Feb, 2021 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today […]
Engitix Therapeutics to relocate headquarters to new life sciences cluster, White City Place
London, UK – December 15, 2020 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP). The move follows […]
Engitix Appoints Eduardo Bravo as Chairman of its Board of Directors
London, UK – December 1, 2020 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based upon its proprietary human extracellular matrix (ECM) platform, today announced the appointment of Eduardo Bravo as Chairman of its Board of Directors. Eduardo has over 25 years […]
Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases
Collaboration combines Engitix’s unique ECM platform with Takeda’s expertise in gastroenterology research and development (R&D) and commercialisation London, UK – 25 August 2020 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today entered into a licensing and collaboration agreement […]
Engitix and Morphic Enter Research Collaboration to Identify ECM-related Targets in Fibrostenotic Inflammatory Bowel Disease (IBD)
London, UK and Waltham, Massachusetts, USA – 10 December, 2019 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, and Morphic Therapeutic (‘Morphic’), a biopharmaceutical company developing oral integrin therapies, today announce that they have entered into a research […]
Engitix Receives a Golden Ticket to LabCentral from Takeda to Advance Fibrosis and Solid Tumour Research
Golden Ticket includes one year of lab bench space at Cambridge, MA-based shared laboratory and office space London, UK, 5 November 2019 – Engitix Ltd (‘Engitix’), a private company focused on drug discovery for fibrosis and solid tumours based on its pioneering human extracellular matrix (ECM) platform, announced that its subsidiary Engitix, Inc, has been awarded a Golden Ticket […]
Engitix Ltd Appoints Gino Van Heeke as Chief Scientific Officer
London, UK, 7 May 2019 – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces the appointment of Gino Van Heeke, PhD, as Chief Scientific Officer (CSO), effective 7th May. Dr Van Heeke has over 20 years of […]
UCL Spin-out Engitix Closes £5m Financing to Progress Liver Disease and Pancreatic Cancer Drug Discovery Platform and Pipeline
London, UK, 27 November 2018 – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces it has closed a £5 million Series A financing, led by a private investor. Engitix has validated its proprietary tissue-specific and disease-specific human […]